Yun-Shiuan O Hsu, I-Wen Wu, Shang-Hung Chang, Cheng-Chia Lee, Chung-Ying Tsai, Chan-Yu Lin, Wan-Ting Lin, Yu-Tung Huang, Chao-Yi Wu, George Kuo, Chih-Yen Hsiao, Hsing-Lin Lin, Chih-Chao Yang, Tzung-Hai Yen, Yung-Chang Chen, Cheng-Chieh Hung, Ya-Chong Tian, Chang-Fu Kuo, Chih-Wei Yang, Gerard F Anderson, Huang-Yu Yang
Hyperuricemia has been associated with chronic kidney disease (CKD) progression. The antihyperuricemic febuxostat's potential renoprotective effect has been demonstrated in stage 1-3 CKD. Large-scale studies comparing the renoprotective potential of febuxostat and allopurinol in advanced CKD are lacking. We exclusively selected 6,057 eligible patients with predialysis stage 5 CKD prescribed either febuxostat or allopurinol using the National Health Insurance Research Database in Taiwan during 2012-2015. There were 69...
May 2020: Clinical Pharmacology and Therapeutics